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Treatment of head and neck cancer with photodynamic
therapy: results after one year
M. G. DILKES, F.R.C.S.(ED.), F.R.C.S., M. L. DEJODE, PH.D., Q. GARDINER, F.R.C.S.,
G. S. KENYON, M.D., F.R.C.S., P. MCKELVIE, M.D., F.R.C.S.
Abstract
Photodynamic therapy (PDT) is a new and promising treatment modality for the treatment of malignant
disease. This paper reports the preliminary experience of our group in the use of this therapy for the
treatment of tumours arising in the head and neck. The majority of treatments in these cases have used a
second generation systemic photosensitizer, weto-tetrahydroxyphenylchlorin (ra-THPC). Two other cases
were treated with either Photofrin 2 (a first generation systemic sensitizer) or with the topical
photosensitizer, delta-aminolaevulinic acid (8-ALA).
The initial results have been encouraging with good clinical responses evident in patients presenting
with a variety of differing tumour types. We feel there is now sufficient evidence of the efficacy of this
treatment to warrant a multicentre prospective study into the treatment of early head and neck cancer
with PDT.
Key words: Head and neck neoplasms; Photochemotherapy
Introduction
A low morbidity alternative form of treatment for
malignancy arising in the head and neck is highly
desirable. The current standard methods of treat-
ment for cancer in this area comprise radiotherapy
and surgery in varying combinations. Both of these
are associated with a significant morbidity and the
overall mortality rates for anything other than early
disease remains high. Moreover surgery in this area
is often both aesthetically and functionally disabling
(especially if it requires wide excision in order to
gain tumour clearance) and radiotherapy carries
with it the risks of disabling side effects including
xerostomia, mucositis, loss of taste and smell,
laryngeal dysfunction and skin erythema: in some
instances skin breakdown or osteoradionecrosis may
also ensue (Johansen et al., 1990).
Photodynamic therapy (PDT) was used initially as
a diagnostic modality (Lipson et al., 1961). The first
clinical therapeutic studies on primary cancer were
performed by Kelly and Snell (1976) but these
introductory trials were dogged by the use of
relatively impure and inefficient drugs haematopor-
phyrin derivative (HpD) and Photofrin 2 (Lederle
Laboratories, Gosport, Hants, UK). Both these early
agents required large drug and high light doses to
achieve a satisfactory clinical effect and this, in turn,
led to prolonged skin light sensitivity. Despite these
problems a significant amount of success was
achieved in the treatment of head and neck
squamous cell carcinomas, particularly in cases of
early disease (Gluckman, 1991). The more recently
derived drugs, refined from the active components of
these early agents, have been shown to have
significant advantages over these initial compounds
(Berenbaum et al., 1989).
The drugs are usually given either intravenously,
or orally, although a newer compound (delta-
aminolaevulinic acid: 8-ALA) has also been admi-
nistered topically. This drug is made from laboratory
8-ALA, in a 20 per cent cream with Unguentum
(Merck). Following administration the drugs accu-
mulate within cells sparing the nucleus and, for
reasons that are unknown, there is preferential take
up by malignant tissue (Dougherty, 1989). While a
minimum concentration of photosensitizer in tissue
needs to be present before a cytotoxic photodynamic
effect will occur there can, theoretically, be complete
sparing of normal tissue if drug levels in normal
tissue are below the threshold for effect whilst they
are above this same threshold in the malignant cell.
This is of importance clinically for the timing of
delivery of the light stimulus following drug delivery
will directly affect both the normal tissue reaction
and the tumoricidal effect. However careful atten-
tion to this can allow effective treatment of the
malignancy with insignificant damage to normal
structures (Chevretton, 1993).
From the Department of Otolaryngology and the Surgical Unit. The Royal London Hospital. Whitechapel. London El IBB.
Accepted for publication: 4 June 1995.
1072TREATMENT OF HEAD AND NECK CANCER WITH PHOTODYNAMIC THERAPY: RESULTS AFTER ONE YEAR 1073
ABSORPTION CHARACTERISTICS
Porphyrin
Transmittance of
light through tissue
Naphthalocyanine
Phthalocyanine
Chiorin
Substituted porphyrin
400 600 800
Wavelength (nanometres)
FIG. 1
The amount of light passing through human tissue 1 cm thick,
related to absorption by porphyrins.
The exact mode of action of the drug after light
activation is unknown but appears to involve the
transformation of the drug to a higher energy state at
the cellular level. In the subsequent decay from this
higher level to the normal steady state free radicals
such as superoxide ions are formed. These sub-
stances oxidize any adjacent biological structures
and, within a cell, this leads to destruction of vital
organelles - with cell death (Weishaupt et al., 1976).
The wavelength of light used to activate the
photosensitizing drug is critical to the depth of the
photodynamic effect because light of different
wavelengths penetrates tissues to different degrees.
Peaks of penetration occur at a wavelength of
around 850 nanometres (nm) (Figure 1), and newer
photosensitizing drugs have therefore been designed
to have a high absorption peak at or around this
wavelength (Bonnet and Berenbaum, 1989).
In this paper we report a series of patients in
whom such second generation photosynthesizers
have been used either as primary or as adjunctive
treatment in patients with head and neck malig-
nancy, along with our early experience using two
other photosensitizing drugs.
Material and methods
Over the course of the 12 months between
December 1992 and December 1993 a series of 17
treatments were given to patients selected for
photodynamic therapy (PDT) on a case by case
basis. Selection was by consultant ENT surgeons and
radiotherapists. Those included were patients who
were not thought to be suitable for standard
treatment or those in whom adjunctive treatment
was thought to be potentially beneficial.
Full informed consent was obtained with particular
attention being paid to warning patients of the
dangers of light exposure following drug administra-
tion. It was decided that both doctors and nurses
should be involved in this counselling and the
treatment would not be offered if any patients
were thought to be at risk of not understanding or
complying with the necessary protocols. In practice
no patient was withdrawn for this reason.
We used a particularly active systemic photosensi-
tizer, meta-tetrahydroxyphenylchlorin (m-THPC) for
15 treatments. The advantages of this drug over
HpD and Photofrin 2 have been outlined in the
introduction and are presented in Table I. In one
early case Photofrin 2 was used because we did not
feel familiar enough with m-THPC at this stage to
use it clinically: in one other case we used a topically
active photosensitizing drug, 8-ALA, for a patient
with an early skin cancer. The patients treated are
detailed in Table II.
Following drug administration a copper vapour
laser pumping a rhodamine dye laser (Oxford
Lasers, Abingdon Rd, Oxford, UK) was employed
to activate the drug. The wavelength used was 652
nanometres (nm) for m-THPC and 630 nm for
8-ALA and Photofrin 2. These wavelengths corre-
sponded with the peak of light absorption in the red
band for each compound and ensured maximal tissue
penetration. Light was delivered down a 600 micron
quartz fibre into a microlens (QLT, Vancouver,
Canada), a cylinder diffuser (PDT systems, San Jose,
California, USA) or a freshly cleaved bare fibre
depending on the site of the tumour. In all cases
using m-THPC the interval between drug and light
administration was 96 hours, the energy density was
100 milliwatts per square centimetre (mW/cm
2) and
the total light dose was 20 Joules per square
centimetre (J/cm
2). Light was delivered to the
tumour so that the angle of incidence was close to
90°, and care was taken to ensure that the distribu-
tion over the irradiated area was as even as possible.
With Photofrin 2 the drug-light interval was 48 hours
and the equivalent of 50 J/cm
2 was applied inter-
stitially to the tumour. In the sole case in which
Purity
Assay
Efficiency
Specificity
Red spectrum peak
Solubility
TABLE I
Photofrin 2/HpD
Difficult to purify
Several active components, therefore difficult to assay
Only moderate, therefore high drug and light doses
needed
Studies show approximately 2:1 tumour to normal
tissue ratio
630 nm
Difficult to dissolve
m-THPC
99% purity available
Single component, easily measured
High efficiency, in the order of 100 X greater
than Photofrin
Available data shows around 6:1 tumour to
normal tissue ratio
652 nm
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8-ALA was utilized the drug was applied as a cream
to the tumour site once excess surface skin cells had
been removed with scraping and adhesive tape. The
cream was left on the tumour for three hours
following which EMLA anaesthetic cream was
applied for one hour prior to light treatment being
given at 150 J/cm
2 with an energy density of 150 mW/
cm
2.
Tumour response was graded using a modification
of the World Health Organization system: (1) ?
Complete. No evidence of tumour macroscopically
during two inspections of the treatment site one
month apart, with a negative biopsy after 12 weeks.
(2) Good. Macroscopic response of tumour, with
reduction in tumour bulk to 50 per cent of the
original size at four weeks. (3) Moderate. Macro-
scopic response of tumour, with some reduction in
tumour bulk at four weeks. (4) Poor. No obvious
response of tumour.
Results
All of the treatments resulted in the tumour visibly
responding to the effects of PDT (see Table II). This
ranged from mild sloughing in the one case where a
poor response occurred (treatment no. 3), to
significant and prolonged sloughing over a period
up to four weeks. Large reactions to the therapy
were characterized by a necrotic smell, which was
treated successfully with oral metronidazole therapy.
The topical treatment with 8-ALA resulted in
erythema of the tumour and some surrounding
skin, followed by a scab formation and regression
of the neoplasm: however this was incomplete. In
those cases where pain was the most significant
symptom (treatment nos. 1, 2 and 9), there was
undoubtedly a reduction in the levels of analgesia
needed after treatment.
Minor complications did occur. In all cases where
m-THPC PDT was used there was local pain in the
arm following the slow intravenous injection of the
drug. This lasted for up to three minutes and was
TABLE II
No. Description Cell TNM FU Dose Response
1 Pyriform fossa post-DXT.
Inoperable due to mental state
SCC 1.5 PF2 Good. Died with residual
tumour
2 Tonsil/floor of mouth. Post-DXT
and surgery
3 Post-nasal space/posterior
faucial pillar. Post-DXT
4 Pyriform fossa
5 Soft palate
6* Tongue base
7* Tongue base
8* Tongue base
9 Tongue base/pyriform fossa.
Post-DXT + surgery
10 Aryepiglottic fold (2nd primary)
11
+ Glottis/supraglottis
12
+ Glottis
13
+ Glottis (laryngofissure
AIOPDT)
14 Neck (after neck dissection
AIOPDT)
15 Neck (after neck dissection -
tumour on carotid, AIOPDT)
16 Maxilla (after maxillectomy,
AIOPDT)
17 Nose (recurrence after surgery)
SCC
SCC
SCC
SCC
MM
MM
MM
SCC
SCC
VCC
VCC
VCC
SCC
SCC
SCC
BCC
T4
No
T,
No
T2
No
T2
No
T2
M,
T2
M,
T2
M,
T4
No
T2
No
T2
T,
T,
N2
N3
T4
T,
12
7
22
20
2
1
12
4
7
2
2
1
1
2
4
2
0.3
0.15
0.15
0.15
0.15
0.15
0.15
0.3
0.15
0.15
0.15
0.15
0.15
0.15
0.15
Cream 8-ALA
Good. Died with residual
tumour
Poor. Lost to follow-up
? Complete
? Complete
Good
Moderate
? Complete
Good. Died at 6 months
? Complete. Died of CVA at 7
months
Good
Good
? (DXT given)
Died at 6/52 no residual disease
Local recurrence
No local recurrence at area
treated
Local recurrence
SCC = Squamous cell carcinoma. VCC = Verrucous carcinoma. MM = Malignant melanoma. BCC = Basal cell carcinoma. FU =
follow-up in months. DXT = radiotherapy. AIOPDT = Adjunctive intraoperative PDT.
All doses are in mg/kg and represent m-THPC intravenously except where stated. 8-ALA = delta-aminolaevulinic acid applied
topically. PF2 = Photofrin 2 intravenously.
*One patient, three sequential treatments at monthly intervals.
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thought to be due to the irritant effect of the dilutant
on the veins. Post-operative pain was also present in
all cases. It tended to start 24 hours after treatment
and last between two and three weeks. In no case
were patients unable to swallow fluids although some
required generous analgesia and could not eat solid
food for up to one week. In addition a very mild
photosensitive reaction occurred in the second case
after the second treatment when the patient, who
was observing all reasonable precautions, sat in front
of a log fire for several hours one evening seven days
after drug administration. The ensuing minor
oedema of the lower eyelid and the back of the
hands lasted approximately four days.
There were no other adverse effects in any of the
other cases treated. Those cases that could be
followed closely showed an initial slough developing
over the treatment site. This came on after approxi-
mately 24 hours, and stayed for up to three weeks.
After five days, however, the slough was only at the
tumour site, the surrounding non-tumour tissue in
the treatment area having undergone mild erythema
and slough formation before returning to normal.
In two cases sequential treatments were given. In
the first of these cases (treatment nos. 6,7, and 8) the
patient suffered with secondary malignant melanoma
and presented with a deposit on the posterior third
of the tongue. The tumour was approximately 3 cm
in diameter. Chemotherapy had failed, radical
surgery was clearly inappropriate and radiotherapy
was held to be ineffective in this disease. A good, but
not complete, tumour regression was achieved with
the first procedure and, when macroscopic evidence
of further disease was seen, second and third
treatments were offered. All visible tumour
regressed and a full resolution of symptoms was
achieved. Twelve months later the patient remains
macroscopically free of tumour and symptom free.
In the second case multiple treatments (treatment
nos. 11, 12 and 13) were performed for a different
reason. On laryngoscopy and biopsy of this patient
verrucous laryngeal carcinoma was reported. Photo-
dynamic therapy was felt to be attractive since the
entire area could be treated uniformly with a single
spot of laser light. The patient in question was
extremely difficult to endoscope. Unfortunately,
despite a good macroscopic reaction of the tumour
to treatment, full regression did not occur: this was
thought to be due to inadequate light delivery and a
second treatment with a different method of delivery
also failed due to the difficult access. A third attempt
was made using photodynamic therapy adjunctively
after a laryngofissure and superpulse carbon dioxide
excision of the tumour. In fact histology then showed
invasive squamous cell carcinoma (SCC) rather than
the previously reported verrucous tumour. Radical
radiotherapy was therefore subsequently given.
In neither of these cases was any adverse reaction
seen from the effects of cumulative therapy.
Discussion
The use of photodynamic therapy seems to offer a
new and useful method of treating and palliating
patients with malignancy in the head and neck.
In particular m-THPC seems to have a great deal of
potential for use at this site. This compound has a
strong absorption peak at 652 nm - giving it a better
depth of penetration than Photofrin 2 or 8-ALA -
and it has a much greater degree of superoxide
generation for a given amount of delivered light
energy. This makes the light and drug doses required
for effective action much smaller. Thus a typical dose
of this drug is only 0.15 mg/kg as compared with 1.0
to 2.0 mg/kg used for Photofrin 2 and, in turn, the
smaller amount of drug halves the time that patients
need to avoid bright sunlight from two months to
one. This is difficult to confirm on a molecular basis
however, since the relative molecular mass of
Photofrin 2 is unknown, due to its exact make up
being unknown. Moreover the light dose needed for
efficient tumour death with m-THPC is also smaller:
only 20 J/cm
2 is required compared to 50-100 J/cm
2
for Photofrin 2 and 150 J/cm* for 8-ALA. This has
the benefit of reducing treatment times. The
differences between the second and first generation
drugs is summarized in Table I.
The intensity of light delivery is limited by the
fibre end output of the copper vapour/rhodamine
laser system. Because treatment areas are often
around 10 cm
2, this limits the light intensity to 100
mW/cm
2 since the maximum output of the laser is
around 1 W in the red spectrum. Whether a better
effect occurs at higher or lower light intensities is
currently unknown, although above 300 mW/cm
2 an
undesirable heating effect will probably occur even
from simple surface illumination.
With new laser systems such as the Laserscope
KTP pumped dye laser (Laserscope UK, Raglan
House, Cwmbran, Gwent) power outputs from the
end of a fibre at 652 nm can be up to 7 W, making
the treatment of larger areas far quicker and easier
to perform.
In this study the drug doses given with Photofrin 2
and 8-ALA were in accordance with previously
recommended treatment protocols (G. Stables,
personal communication). For treatment using
m-THPC drug doses of either 0.3 mg/kg or 0.15
mg/kg were used: the lower dose, which seems
equally effective, is now preferred since it reduces
problems with skin sensitivity. The light parameters
used were chosen on the basis of experimental work
(Ris et al., 1993; Dilkes, 1995) as was the time delay
between drug and light administration. Current
research is aimed at further reducing the drug dose
of m-THPC and increasing the light fraction while
ensuring continued clinical efficacy.
Because malignant melanoma may regress spon-
taneously it may be that the inflammatory reaction
set up in the tumour during treatment (treatment
nos. 6, 7 and 8) was enough to stimulate an otherwise
quiescent immune response. However the case
demonstrates that the sequential administration of
photodynamic therapy is possible. It also illustrates
that tumours deeper than 1 cm can be successfully
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which involved a substantial depth of the tongue, led
to the eventual disappearance of the tumour. There-
fore photodynamic therapy might also be useful for
later disease which recurs locally after surgery and
radiotherapy.
Delta-aminolaevulinic acid (8-ALA) is a different
form of compound from the more classical photo-
sensitizers. It acts by being rapidly metabolized into
an active photosensitizing agent, protoporphyrin 9
(PP9) which is then slowly metabolized into haem (a
rate-limiting step). Active photosensitization only
occurs during a fairly short period of time when PP9
levels are high and this obviates problems with skin
sensitization if applied topically. However due to its
relative inefficiency compared to m-THPC it can
only be used to treat very superficial lesions such as
early basal cell carcinoma. While the amount of light
needed for a good clinical effect appears to be circa
150 J/cm
2, which increases the treatment time
compared to m-THPC, the fact that it is effective
topically is enough to make this a very exciting
compound for full scale clinical use. However as the
case presented here illustrates (treatment no. 17), it
is only useful for the most superficial of lesions.
While an intense tumour reaction to treatment was
seen clinically in this case the neoplasm was,
presumably, too deep for a curative effect to have
been achieved.
While primary therapy of early cancers is thought
to be one of the most encouraging areas of PDT
treatment (Monnier et al., 1990), adjunctive therapy
also seems to have exciting possibilities. Such
treatment could theoretically be used during surgery
in the expectation that microscopic tumour residue
will be eradicated. Animals studies have shown that
the local recurrence of tumours after resection can
be reduced by up to 50 per cent with adjunctive PDT
(Davis et al., 1990; Dilkes, 1995). Safety work on the
effects of m-THPC PDT on arteries has shown it to
be safe when the drug and light doses and drug-light
time intervals outlined are observed (Dilkes, 1995).
We have no experience that we can report of
reducing tumour bulk prior to surgical resection but
we have successfully given photodynamic therapy
during surgery in three cases. Such intraoperative
therapy has been used with no adverse effects even
when treatment was delivered directly to the carotid
artery as part of a radical neck dissection (treatment
nos. 14 and 15).
Due to the small numbers and relatively short
period of follow-up it is not possible to make any
definite claims as to the efficacy, or not, of this form
of treatment for head and neck cancer. There is no
doubt that it offers a low morbidity form of
treatment for this condition however. We feel that
the results presented here are encouraging particu-
larly with respect to the treatment of early malig-
nancy with m-THPC PDT. We have instigated a
multicentre study looking at the primary treatment
of selected cases of head and neck mucosal
malignancy. Although there have been several
small series describing good results with this form
of therapy, no large multicentre trial has yet been
conducted either with the older or the newer drugs.
PDT appears to have few side effects and is easily
administered either as primary or adjunctive ther-
apy. In addition treatment can be repeated with
safety in the same patient.
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